文献速递系统性红斑狼疮

EQ-5D-3L完全健康状态可区分SLE临床试验中的药物与安慰剂

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于BLISS-52和BLISS-76试验(N=1684)的数据,研究EQ-5D-3L完全健康状态(FHS)在SLE临床试验中的区分能力。结果显示,标准治疗联合贝利尤单抗组FHS频率高于标准治疗组(26.1% vs 19.4%;P=0.001;第52周),SRI-4应答者高于非应答者(27.0% vs 19.8%;P<0.001;第52周)。多变量回归中,SLEDAI-2K和SLICC/ACR损伤指数评分与较低FHS频率独立相关,而贝利尤单抗10 mg/kg联合标准治疗有利于FHS感知(OR:1.60;95%CI:1.15,2.24;P=0.006)。

要点

  • EQ-5D-3L FHS可区分贝利尤单抗与安慰剂,以及SRI-4应答者与非应答者。
  • SLEDAI-2K和SLICC/ACR损伤指数评分越高,第52周FHS频率越低。
  • 贝利尤单抗10 mg/kg联合标准治疗与更高FHS感知独立相关。

核心结论

  • EQ-5D-3L FHS可区分贝利尤单抗与安慰剂,以及应答者与非应答者,并在亚组分析中显示已知组效度。

研究设计与样本

  • 利用BLISS-52(NCT00424476)和BLISS-76(NCT00410384)贝利尤单抗试验的数据(N=1684)。
  • FHS定义为EQ-5D-3L五个维度均无问题,指数评分为1。
  • 采用Pearson χ2或Fisher精确检验进行比较,逻辑回归用于调整和评估独立性。

主要发现

  • 第52周,标准治疗联合许可剂量贝利尤单抗组FHS频率高于标准治疗组(26.1% vs 19.4%;P=0.001)。
  • 第52周,SRI-4应答者FHS频率高于非应答者(27.0% vs 19.8%;P<0.001),从第36周至第52周均如此。
  • 多变量回归中,SLEDAI-2K(OR:0.90;95%CI:0.87,0.94;P<0.001)和SLICC/ACR损伤指数(OR:0.79;95%CI:0.69,0.91;P=0.001)评分与第52周较低FHS频率独立相关。
  • 标准治疗联合贝利尤单抗10 mg/kg与FHS感知独立相关(OR:1.60;95%CI:1.15,2.24;P=0.006)。
  • 联合贝利尤单抗10 mg/kg在抗疟药使用者中FHS频率高于非使用者(29.9% vs 20.1%;P=0.011),在抗dsDNA和抗Sm阳性患者中分别高于阴性患者(31.4% vs 13.4%;P<0.001和33.0% vs 22.6%;P=0.010),而单用标准治疗组无显著差异。

关键数值与推荐

  • FHS定义为EQ-5D-3L五个维度均无问题,指数评分为1。
  • 第52周标准治疗联合许可剂量贝利尤单抗组FHS频率26.1% vs 标准治疗组19.4%(P=0.001)。
  • 第52周SRI-4应答者FHS频率27.0% vs 非应答者19.8%(P<0.001)。
  • 贝利尤单抗10 mg/kg联合标准治疗与FHS感知的OR为1.60(95%CI:1.15,2.24;P=0.006)。

临床怎么用

  • EQ-5D-3L FHS可能作为SLE研究中有用的患者报告结局指标。
  • 在SLE临床试验中,FHS可辅助区分治疗效应和应答状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and to identify factors associated with FHS after treatment. METHODS: Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belimumab (N = 1684) were utilized. FHS was defined as a response of no problems in all five EQ-5D-3L dimensions, yielding an index score of 1. The Pearson's χ2 or Fisher's exact test was employed for comparisons, and logistic regression for adjustments and assessment of independence. RESULTS: We demonstrated higher EQ-5D-3L FHS frequencies among patients given standard therapy (ST) plus the licensed belimumab dose vs ST alone (26.1% vs 19.4%; P = 0.001; week 52), and within SRI-4 responders vs non-responders (27.0% vs 19.8%; P < 0.001; week 52) from weeks 36 to 52. In multivariable regression analysis, SLEDAI-2K (OR: 0.90; 95% CI: 0.87, 0.94; P < 0.001) and SLICC/ACR Damage Index (OR: 0.79; 95% CI: 0.69, 0.91; P = 0.001) scores were independently associated with lower FHS frequencies at week 52, while adding monthly infusions of belimumab 10 mg/kg to ST favoured FHS perception (OR: 1.60; 95% CI: 1.15, 2.24; P = 0.006). Add-on belimumab 10 mg/kg yielded higher FHS frequencies in antimalarial users vs non-users (29.9% vs 20.1%; P = 0.011), and in anti-dsDNA- and anti-Sm- positive vs negative patients (31.4% vs 13.4%; P < 0.001 and 33.0% vs 22.6%; P = 0.010, respectively), whereas no significant differences were observed in patients given ST alone. CONCLUSION: EQ-5D-3L FHS distinguished belimumab from placebo and responders from non-responders, and exhibited known-group validity in subgroup analysis. FHS may prove a useful patient-reported outcome in SLE studies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lindblom J, Gomez A, Borg A, et al. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33502473. doi:10.1093/rheumatology/keab080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。